Home
Company
About us
Management
Board of Directors
Scientific Advisory Board
Partnerships
Partnerships
Nox Science
NOX Enzymes
NADPH Oxidase
NOX Enzyme Family
NOX Expression
NOX and Disease
Oxidative Stress and Disease
Physiological Functions of NOX
Fibrotic diseases
Neurodegenerative diseases
Cardiovascular diseases
Publications
Pipeline
GKT831
GKT771
Research programs
Investors
Message from the CEO
Stock information
Analyst coverage
Contribution project
Press release
Project presentation
Documentation
Shareholders general meeting
Press releases
2017
2016
2015
2014
Events and presentations
Regulated information
Financial information
2017
2016
2015
2014
Other regulated information
2017
2016
2015
2014
Governance
Shareholder information
Shareholders’ newsletters
2017
2016
2015
2014
Shareholders’ meetings
2017
AGM of June 15, 2017
AGM of February 28, 2017
2016
2015
2014
Agenda
News and Events
Press releases
2017
2016
2015
2014
Events and presentations
Media
Press clippings
Interviews
Contacts
News
See all news
Prev
Next
2017-09-21 - 18:45
2017 first-half results
2017-08-03 - 17:45
Genkyotex’s GKT831 Shown to Delay Tumor Growth in Multiple Preclinic...
2017-07-27 - 18:00
Genkyotex provides business update for Q2 2017
2017-06-28 - 18:00
Genkyotex Announces Investigator-Initiated Phase 2 Clinical Trial to E...
2017-06-27 - 18:00
Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in...
2017-05-02 - 21:15
Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in...
2017-04-27 - 19:06
Genkyotex provides business update for Q1 2017
2017-03-14 - 18:00
Genkyotex to participate in the 1st Annual H.C. Wainwright NASH Invest...
Events
See all events
Prev
Next
2017-09-07 - 09:08
Investor Presentation August 2017
2016-03-14 - 18:30
2015 Annual Results
2015-10-07 - 18:30
Large & Midcap Event
2015-09-23 - 18:30
Analysts call on HY 2015 results
2015-09-22 - 18:30
Half-year financial results 2015
2015-06-22 - 18:30
France Biotech Lifesciences Days
